Primary duodenal follicular lymphoma: 6-years complete remission after combined radio-immunotherapy by Franco, P et al.
See	discussions,	stats,	and	author	profiles	for	this	publication	at:	https://www.researchgate.net/publication/51590020
Primary	duodenal	follicular	lymphoma:	6-years
complete	remission	after	combined	radio-
immunotherapy
Article		in		Acta	gastro-enterologica	Belgica	·	June	2011
Source:	PubMed
CITATION
1
READS
94
8	authors,	including:
Pierfrancesco	Franco
Università	degli	Studi	di	Torino
126	PUBLICATIONS			706	CITATIONS			
SEE	PROFILE
Andrea	Riccardo	Filippi
Università	degli	Studi	di	Torino
91	PUBLICATIONS			786	CITATIONS			
SEE	PROFILE
Patrizia	Ciammella
Azienda	Ospedaliera	Santa	Maria	Nuova	di	R…
58	PUBLICATIONS			427	CITATIONS			
SEE	PROFILE
Corrado	Tarella
Università	degli	Studi	di	Torino
63	PUBLICATIONS			1,944	CITATIONS			
SEE	PROFILE
All	content	following	this	page	was	uploaded	by	Pierfrancesco	Franco	on	29	November	2016.
The	user	has	requested	enhancement	of	the	downloaded	file.
Primary duodenal follicular lymphoma : 6-years complete remission after
 combined radio-immunotherapy
Pierfrancesco Franco1, Andrea Riccardo Filippi1, Patrizia Ciammella1, Angela Botticella1, Agnieszka Namysl-Kaletka2,1,
Alberto De Crescenzo3, Corrado Tarella3, Umberto Ricardi1
(1) Department of Medical and Surgical Sciences, Radiation Oncology Unit, University of Torino, Ospedale S. Giovanni Battista, Turin, Italy; (2) Department of Radio -
therapy, Center of Oncology, Maria-Sklodowska-Curie Memorial Institute, Gliwice, Poland; (3) Hematology and Cell Therapies Unit, University of Torino, Ospedale
Umberto I, Turin, Italy.
Abstract
Primary gastrointestinal lymphoma (PGL) is known to account
for 40% of all extranodal non-Hodgkin’s lymphomas (NHLs) and
between 4% to 12% of all NHLs. The small intestine is the site of
presentation in 20-30% of cases, with the terminal ileum usually
involved. Duodenal localizations have always been thought to be
rare, but are presently growing in incidence. We herein report on a
case of Stage IV primary duodenal FCL, located to the second por-
tion of the duodenum with concomitant minimal bone marrow
involvement. The patient was frontline approached with a conser-
vative combined modality treatment consisting of 4 weekly infu-
sions of the chimeric human-murine IgG1 mono-clonal antibody
against the B-cell surface antigen CD-20, Rituximab (375 mg/m2)
and consolidation 3D conformal external beam radiotherapy up to
a total dose of 36 Gy given into 20 fractions to the involved duode-
nal portion. Six years after treatment has been completed, the
patient is free from disease with no treatment-related toxicity. (Acta
gastro enterol. belg., 2011, 74, 337-342).
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Introduction
Primary gastrointestinal lymphoma (PGL) is known
to account for 1 to 4% of all gastro-intestinal malignan-
cies (1). Moreover, the gastro-intestinal tract as a site of
origin for non-Hodgkin’s lymphomas (NHLs) includes
from 4 to 12% of them and 40% of all extranodal
NHLs (2). While the stomach is the most common site of
involvement, accounting for approximately 50-60% of
all cases, the small intestine is the primary location in 20-
30%. It often occurs within the terminal ileum, whereas
duodenal localizations have always been thought to be
rare, but are presently growing in incidence (2-4).
Concerning histology, high-grade diffuse large B-cell
lymphoma and mucosa-associated lymphoid tissue lym-
phoma (MALT lymphoma) represent the vast majority of
PGLs ; follicular cell lymphoma (FCL) accounts for only
1-7% of them (4-7). Primary FCL of the duodenum is a
rare disease that has been recently recognized as a dis-
tinct clinico-pathologic entity. A few studies of duodenal
FCL have shown that it has features similar to those of
conventional nodal follicular lymphoma with an indolent
clinical course and immuno-histological features undis-
tinguishable from nodal follicular lymphoma (8). We
herein report on a case of Stage IV primary duodenal
FCL, located to the second portion of the duodenum with
concomitant minimal bone marrow involvement. The
treatment approach consisted of combined immuno-
 radiation which achieved a long lasting complete remis-
sion.
Case report
In 2003, a 42 aged healthy women was referred to our
institutional hospital, due to the recent appearance of
 epigastric discomfort usually worsening shortly after
food intake, accompanied by nausea sensation and
 sporadic vomiting. Patient’s previous medical history
was silent, apart from a minimal change in bowel habits
and a slight weight loss during the last four months.
Physical examination could not reveal any remarkable
finding, with no superficial lymphadenopathy detectable.
Moreover no hepato-splenomegaly or cutaneous lesions
could be highlighted. Complete blood count and serum
biochemistry were performed, but all findings were
 within normal limits. However, serum anti-Helicobacter
Pylori antibodies were demonstrated as positive
(65 U/ml). Thereby, to confirm clinical suspicious, an
upper gastrointestinal endoscopy was performed, with the
evidence of a duodenal granular flat elevated mucosal
lesion, irregularly shaped and composed of whitish,
coarsely lumped, polypoid raised granules (Fig. 1a). The
patient subsequently underwent a punch biopsy of the
lesion showing the presence of neoplastic follicles com-
posed predominantly of small-to-medium-sized cleaved
cells (centrocytes) with scattered small round lympho-
cytes. Immunostaining showed that atypical cells were
positive for antibodies directed towards the B-lineage
antigens such as L-26, CD 10, CD 20, Cd79a, CD 75 and
BCL-2, (intensely positive in the nodule center) and
 negative for CD5 and CD3, CD23 and cyclin D1. A diag-
nosis of lymphoma was made and it was classified
according to the Revised European-American
Lymphoma Classification as a follicle center lymphoma,
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was repeated in order to evaluate FCL response to ritux-
imab. The examination demonstrated a partial response
of the duodenal lesion, diminishing in size and thicken-
ing (Fig. 1b). In order to consolidate rituximab results,
the patient underwent a full course of external beam
 radiation therapy delivered with a three-dimensional
conformal filed arrangement (Fig. 2). The conventional-
ly fractionated total dose was up to 36 Gy given in
20 fractions. Localization of the lesion was facilitated by
the placement of a metallic clip in the peri-lesional region
during the endoscopic restaging procedure (Fig. 1c). No
acute toxicity could be recorded. One month after RT had
been completed, a re-evaluation endoscopy showed a
complete disease remission with the total disappearance
of the duodenal lesion (Fig. 1d). The first bone marrow
aspiration, performed at six months, showed the persist-
ence of minimal residual disease (MRD) with nested
Polymerase Chain Reaction (PCR) for Bcl-2/Ig-H
translocation. At one year, a second biopsy demonstrated
the achievement of a molecular remission (MR) status.
Six years after treatment the patient is still in complete
maintained MR. No treatment-related toxicity has yet
been recorded up to last follow-up examination.
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follicular, grade 1. Moreover, no evidence of Helico -
bacter Pylori could be detected after gastrointestinal
endoscopy.
A complete staging work-up was performed.
Endoscopic ultrasonography (EUS) demonstrated a sub-
stantial thickening of the mucosal and submucosal layers
of the 2nd portion of duodenal wall with the synchronous
evidence of multiple hypoechoic granules. A complete
enteroscopy procedure was performed with the ingestion
of a wireless capsule in the shape of videocapsule
endoscopy (VCE). Lesions were uniquely located within
the duodenum. A computed tomography scans of the
chest, abdomen and pelvis failed to show any lymph
node enlargement. Bone marrow aspiration showed a
minimal invasion by small sized cleaved cells. The
tumour was staged as IV due to bone marrow involve-
ment (according to Musshoff’s modification of the Ann
Arbor classification) (9). The patient was first
approached with immunotherapy including a weekly
infusion of the chimeric human-murine IgG1 mono-
clonal antibody against the B-cell surface antigen CD-
20, Rituximab (375 mg/m2). After completion of
immunotherapy, an upper gastrointestinal endoscopy
Fig. 1. — Granular flat elevated mucosal vegetation of the duodenum at diagnostic upper gastrointestinal endoscopy (a) ; partial
remission of the macroscopic lesion after 4 cycles of Rituximab (b) ; metallic clip placed during restaging endoscopy (c) ; complete
remission after 36 Gy external beam radiation therapy (d).
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Discussion
Early reports have stated that duodenal lymphomas
are a rare clinicopathological entity, since gastro-intes-
tinal tract (GI) lymphomas mainly involve the stomach
and the colorectum. However follicular cell histology is
a frequent finding among them (3,10). LeBrun et al.
described 31 cases of follicular cell lymphomas (FCL) of
the GI tract in which lesions were predominantly located
within the small intestine (55%), showing a peculiar
predilection for the terminal ileum. No mention was
made about the exact number of duodenal cases (8).
More recently, Yoshino et al. reported a high incidence of
follicular duodenal lymphoma (4). In their series, 8 out
of 222 cases (3.6%) arose from the GI mucosa. Among
them, 5 out of 8 cases belonged to the duodenum. When
these data have been updated, 52 extranodal follicular
lymphomas out of 550 (10%) were described ; among
them 40 cases were located within the duodenum. The
authors observed that this finding might be due to the
usual exploration of duodenal tract during routine endo-
scopies which is of common practice among the
Japanese population (11). Duodenal FCL seems to share
some common characteristics with nodal ones such as
the indolent nature, the female predominance, the occur-
rence in the fourth or fifth decade of life and a supposed
excellent outcome (12). Moreover, a predilection for the
second portion of the duodenum in the region surround-
ing the ampulla of Vater has been noted by some authors.
Several hypotheses have been raised in order to explain
this characteristic. Firstly, a regional quantitative differ-
ence in the amount of intestinal lymphoid tissue and sec-
ondly, a possible role of bile salts and pancreatic juice in
acting as a carcinogen stimulation (13). Adjunctively,
regional lymphnode involvement has frequently been
found in duodenal FCLs, even if the primary lesion only
involves the submucosal layer. This may be due to the
regional anatomical peculiarities with intricate muscular
layers allowing lymphoma cells to easily infiltrate
regardless of biological intrinsic aggressiveness or sys-
temic diffusion tendency (14). Treatment options have
been various such as surgical resection, radiation therapy
(RT), chemotherapeutic agents (CT), immunomodulator,
eradication therapy and several therapeutic combinations
(Table I) but a combined CT-immunotherapy approach
could be considered as a standard option (15). Generally
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Fig. 2. — Antero-posterior view on digitally reconstructed radiographies (a,b) ; evidence of metallic clip (arrow) during simulation
fluoroscopy (c) ; anterior electronic portal image with radio-opaque clip (arrow) acquired during treatment (d).
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Table 1. — Overview of all reported cases
F : female ; M : male ; NA : not available ; NR : not reported ; R : rituximab ; CVP : cyclophosphamide, vincristine, prednisone ; CHOP : cyclophos-
phamide, doxorubicin, vincristine, prednisone  ; CR : complete remission ; PR : partial remission ; SD : stable disease ; NED : no evidence of disease
; AWD : alive with disease ; LAC : lansoprazole, amoxicillin, clarithromycin ; O : observation ; CT : chemotherapy ; RT : radiotherapy ; S : surgery ;
PD : pancreatoduodenectomy ; ppPD : pylorus preserving pancreatoduodenectomy ; E : eradication ; NR : no response.
Reference Pts Sex Duodenal Grade Stage Therapy Outcome
Portion
CT-Rituximab
Ahmed et al. (19) 1 F 2nd 1 IIA CVP ; R CR at 2 years
Esaki et al. (20) 1 M 1st - 2nd NR IIA R-CHOP PR at 6 months
Aguiar et al. (21) 1 NA NA NA I R CR 
Tsujioka et al. (22) 8 4F/4M Ampulla of Vater 1 IAE R-CHOP 7/8 CR at 39 months
Isogai et al. (23) 1 NA NA NA NA R-CHOP NA
Al-Salman et al. (24) 1 M Whole jejunum/3rd NR IV R-CHOP CR after therapy
CT-Rituximab-RT
Zenda et al. (25) 1 F Ampulla of Vater 1 I R-CHOP ; 4Gy RT CR after therapy
Exclusive surgery 
Tanaka et al. (14) 1 F 3rd 1 IA PD NR
Matsuzawa (26) 1 F 2nd 3 II1 PD CR at 2 years               
Adiuvant CT
Yoshino et al. (15) 5 F 2nd 1 I-II S Alive at 2-50 months
Surgery + RT
Misdraji et al. (13) 1 F Ampulla of Vater 1 II 10 Gy Pre-op RT CR after 5 months
PD
36 Gy Post-op RT
Eradication therapy
Higuchi et al. (27) 1 M 2nd/jejunum 1 I LAC SD at 5 months
Toyoda et al. (28) 1 M Ampulla of Vater 2 IE LAC CR at 2 years
Exclusive radiation
Takamura et al. (29) 1 M 2nd – 3rd 1 IA 30 Gy RT CR at 3 years
Miscellaneous
Bende et al. (12) 3 3 F Duodenum NR IE 2 RT only NED at 24-60 months
1 CT only
Born et al. (30) 1 F Whole/jejunum 1 IA None NR
Nakase et al. (31) 1 F Papilla of Vater NR IA NR NR
Mori et al. (32) 1 NA NA NA NA NA NA
Tang et al. (33) 1 M 2nd NR I None SD 
Ridondo-Cerezo (34) 1 F 2nd NR NR Laparoscopy/CT NR
Katsuki et al. (35) 1 NA NA NA Early S NA
Takikawa et al. (36) 1 NA NA NA NA S NA
Sasaki et al. (37) 1 NA NA NA NA R NA
Sato et al. (11) 40 17 F 38 2nd 4 G2 30 IE 13 O 13 AWD 2-61 mo
23 M 2 2nd + 3rd 36 G1 7 IIE 5 PD 5 NED 17-50 mo
3 III E 3 ppD 3 NED 13-32 mo
2 CT 2 AWD at 4-5 mo
2 R-CT 1 NED at 24 mo
1 AWD at 12 mo
5 E 5 AWD at 6-60 mo
1 E + R-CT 1 NED at 12 mo
1 CT-RT 1 NED at 18 mo
8 NR NR
Shia et al. (38) 10 7 M 7 duodenum 6 G1 6 IE 3 O AWD at 2-69 mo
3 F 3 duodenum/jejunum 4 G2 4 IIE 2 S 1 NED at 33 mo/1 DOD 
1 S + CT NED at 73 mo
3 CT 2 NED at 10-55mo
1 AWD at 6 mo
1 CT/RT 1 AWD at 44 mo
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speaking, FCL is usually characterised by an indolent
course and a median survival of 10 years or even more.
The vast majority of strategies employed in FL patients
with curative intent achieves complete remission in most
patients. Unfortunately, the clinical course is usually
characterised by multiple relapses. Regardless of the ini-
tial treatment chosen, most patients eventually die of
lymphoma (16). The use of combination CT guaranteed
a major impact in terms of high complete remission rates
but did not change the overall survival pattern. High dose
therapy with autologous bone marrow transplantation,
given either to consolidate remission or as an upfront
strategy, may improve remission duration, but it has not
shown to improve survival. On the contrary, incumbent
toxicity in terms of myelodysplastic syndromes has been
described. Most studies suggest that early treatment dose
not appear to prolong the survival of asymptomatic
patients. In this context, the observation from Stanford of
an equal survival between asymptomatic patients man-
aged with expectancy until symptoms appear and those
deemed to need therapy immediately properly led to the
widespread acceptance of the so called ‘benign neg-
lect’(15). More recently, the anti CD-20 monoclonal
antibody Rituximab proved to be effective against CD-20
positive low-grade follicular lymphoma, with high
response rates in combination with conventional CT and
even in CT-refractory patients. Adjunctively, treatment-
related toxicity has been reported to be mild and pri-
marly limited to infusion-related events (17). Our group
previously reported on the use of rituximab and radiation
in localized nodal and extranodal FCL (18), with prom-
ising results either in terms of disease control (both local
and systemic) and treatment-related toxicity. In this con-
text, in order to combine and effective local treatment
with a systemic approach able to clear bone marrow from
neoplastic clones, with a concomitant attention towards a
low toxicity profile we chose to treat the patient with
combined rituximab and radiation. In this way we have
been able to perform a conservative approach, avoiding
both surgical excision (which might have been associat-
ed with a high morbidity considering the anatomical site
involved) and CT-related side effects and sequelae with
an excellent clinical outcome. The sequential approach
(rituximab prior to consolidation radiotherapy) lead to
the possibility of a shrinkage of the duodenal lesion
allowing the reduction of both radiation treatment
 volumes and doses, diminishing the probability of RT-
related acute and chronic effects.
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